Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Base de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Gan To Kagaku Ryoho ; 50(4): 493-495, 2023 Apr.
Artículo en Japonés | MEDLINE | ID: mdl-37066465

RESUMEN

Hyperammonemia induced by 5-fluorouracil(5-FU)is known as a rare adverse event, but there are few reports of hyperammonemia occurring during FP(5-FU plus CDDP)treatment for esophageal cancer. We report a case of esophageal cancer with consciousness disorder due to hyperammonemia during FP treatment with an examination of some of the relevant literature. The patient was a man of approximately 70 years of age who was received FP treatment. He showed consciousness disorder on day 4. A blood test showed hyperammonemia(427µg/dL), which was considered to be the cause of his consciousness disorder. He was treated with branched chain amino acid infusion, lactulose and kanamycin and made a full recovery. An operation for esophageal cancer was performed after 3 months and he is currently followed up without recurrence. Hyperammonemia should be considered as a differential diagnosis of consciousness disorder during chemotherapy including 5-FU.


Asunto(s)
Neoplasias Esofágicas , Hiperamonemia , Masculino , Humanos , Hiperamonemia/inducido químicamente , Hiperamonemia/tratamiento farmacológico , Trastornos de la Conciencia/inducido químicamente , Fluorouracilo , Neoplasias Esofágicas/tratamiento farmacológico , Neoplasias Esofágicas/etiología , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos
2.
Gan To Kagaku Ryoho ; 50(13): 1697-1699, 2023 Dec.
Artículo en Japonés | MEDLINE | ID: mdl-38303177

RESUMEN

In cases of unresectable, locally advanced esophageal cancer, conversion surgery may be considered if chemotherapy produces favorable results and surgical resection is indicated. The use of immune checkpoint inhibitors in chemotherapy for esophageal cancer has expanded, and has increased the number of cases in which conversion surgery becomes possible. The patient in the present report had received a diagnosis of Stage Ⅳa esophageal carcinoma, and a prior nephroureterectomy discouraged the administration of platinum-based agents. Nivolumab and ipilimumab were administered as induction chemotherapy. Despite the achievement of stable disease, the patient's esophageal stricture deteriorated, necessitating surgical intervention. The resected specimen revealed that fewer than 50% of malignant cells remained viable and residual cancer cells were noticeably absent, particularly in the enlarged lymph nodes. We herein present the details of this case and discuss the literature concerning surgery following immune checkpoint inhibitor therapy.


Asunto(s)
Neoplasias Esofágicas , Linfadenopatía , Humanos , Nivolumab/uso terapéutico , Ipilimumab/uso terapéutico , Inhibidores de Puntos de Control Inmunológico/uso terapéutico , Neoplasias Esofágicas/tratamiento farmacológico , Neoplasias Esofágicas/cirugía , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico
3.
Gan To Kagaku Ryoho ; 38(12): 2366-8, 2011 Nov.
Artículo en Japonés | MEDLINE | ID: mdl-22202384

RESUMEN

In over the 10 years from 2000-2010, 21 gastric cancer patients received loco-regional chemotherapy with home enteral nutrition (HEN) at an outpatient clinic because of insufficient oral intake. These loco-regional chemotherapy regimens consisted of 5 intra-aortic chemotherapies, 4 hepato-arterial infusions and 12 intra-peritoneal chemotherapies. Five out of 8 cases that had measurable lesions showed PR, and 3 cases revealed PD. The patients received HEN with peptide central formula, 400-1,200 kcal/day in night time. The average duration of HEN was 12.9 months. The post-operative nutritional management was needed for continuation and securing of outpatient chemotherapy. The author reported an experience of the outpatient loco-regional chemotherapy with HEN for the gastric cancer patients who could not eat a sufficient volume of food.


Asunto(s)
Antineoplásicos/uso terapéutico , Nutrición Enteral , Neoplasias Gástricas/terapia , Anciano , Instituciones de Atención Ambulatoria , Antineoplásicos/administración & dosificación , Femenino , Servicios de Atención de Salud a Domicilio , Humanos , Masculino , Estadificación de Neoplasias , Neoplasias Gástricas/patología , Neoplasias Gástricas/cirugía
4.
Ann Nucl Med ; 22(7): 635-9, 2008 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-18756367

RESUMEN

Tumors producing granulocyte colony stimulating factor (G-CSF), malignant lung tumors in most cases, are rare, and patients present with abnormal elevations of the white blood cell (WBC) count in the absence of any infectious disease. We present the (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) imaging findings of two cases of G-CSF-producing tumor. PET-CT showed abnormally high uptake of (18)F-FDG not only by the tumor itself but also diffusely throughout the bone marrow. Following resection of the tumor, the blood G-CSF level as well as the WBC count dropped down to normal range in both cases. Histopathological examination of the resected tumor specimens revealed the presence of an enormous number of inflammatory cells within the tumors and positive immunostaining of the tumor cells for G-CSF. The (18)F-FDG-PET/CT findings could be explained by the elevated bone marrow metabolism associated with the excessively active production of granulocytes under G-CSF stimulation, and the (18)F-FDG uptake by the inflammatory cells also contributing to the total tumor uptake of (18)F-FDG. These characteristic imaging findings are expected to be useful for the diagnosis of G-CSF-producing tumors.


Asunto(s)
Adenocarcinoma/patología , Carcinoma de Pulmón de Células no Pequeñas/diagnóstico por imagen , Carcinoma de Pulmón de Células no Pequeñas/metabolismo , Carcinoma/diagnóstico por imagen , Carcinoma/metabolismo , Factor Estimulante de Colonias de Granulocitos/metabolismo , Neoplasias Pulmonares/diagnóstico por imagen , Neoplasias Pulmonares/metabolismo , Anciano , Médula Ósea/diagnóstico por imagen , Médula Ósea/patología , Carcinoma/patología , Carcinoma de Pulmón de Células no Pequeñas/patología , Fluorodesoxiglucosa F18/farmacocinética , Granulocitos/metabolismo , Granulocitos/patología , Humanos , Recuento de Leucocitos , Neoplasias Pulmonares/patología , Masculino , Persona de Mediana Edad , Tomografía de Emisión de Positrones , Tomografía Computarizada por Rayos X
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA